MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Anxiety influences the neural correlates associated with freezing of gait in Parkinson’s disease

    K. Ehgoetz Martens, M. Georgiades, M. Gilat, J. Hall, J. Shine, C. Walton, S. Lewis (Camperdown, Australia)

    Objective: To evaluate whether Anxious Freezers have altered brain activity during FOG episodes compared to Non-Anxious Freezers. Background: A growing amount of research has emphasized…
  • 2017 International Congress

    Altered attentional brain network in Parkinson’s disease with mild cognitive impairment

    J.H. Yang, K. McMahon, D. Copland, G. Byrne, A. Toft, L. Mithcell, J. O'Sullivan, N. Dissanayaka (Herston, Australia)

    Objective: To investigate alterations in the attention network in Parkinson’s disease patients with mild cognitive impairment (PD-MCI). Background: MCI is a risk factor for dementia…
  • 2017 International Congress

    Altered intrinsic brain functional connectivity in drug-naïve Parkinson’s disease with LRRK2 mutation

    Y. Hou, C. Luo, J. Yang, R. Ou, W. Song, Y. Chen, Q. Gong, H. Shang (Chengdu, China)

    Objective: This study aimed to compare the alterations in the cortico-striatal functional connectivity (FC) of drug-naïve Parkinson’s disease (PD) patients with the leucine-rich repeat kinase…
  • 2017 International Congress

    Grey matter abnormalities associated with early cognitive decline in Parkinson’s disease

    A. Moonen, R. Lopes, A. Leentjens, A. Duits, K. Dujardin (Maastricht, Netherlands)

    Objective: To identify patterns of grey matter (GM) abnormalities in patients with Parkinson's disease (PD) with different cognitive profiles.  Background: Cognitive symptoms occur already in…
  • 2017 International Congress

    Brain PET metabolic substrate of Impulse Control Disorders in Parkinson’s Disease

    E. Robin, A. Verger, F. Fluchere, T. Witjas, J.P. Azulay, E. Guedj, A. Eusebio (Marseille, France)

    Objective: The aim of this study was to describe the cerebral metabolic PET substrate and related connectivity changes in Parkinson's disease patients with impulse control…
  • 2017 International Congress

    Substantia nigra area evaluated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson’s disease

    M. Fabbri, S. Reimão, M. Carbalho, R. Nunes, D. Abreu, L. Guedes, R. Bouça, P. Lobo, C. Godinho, M. Coelho, N. Gonçalves, M. Rosa, A. Antonini, J. Ferreira (Lisbon, Portugal)

    Objective: to investigate the pattern of substantia nigra - neuromelanin (SN-NM) area loss and contrast ratio (CR) intensity changes in late-stage Parkinson’s disease (LSPD) patients,…
  • 2017 International Congress

    The involvement of primary olfactory cortex in olfactory deficits in early-stage Parkinson’s disease

    J. Wang, T. Subramanian, Q. Yang (Hershey, PA, USA)

    Objective: To determine if the primary olfactory cortex (POC) is involved in the olfactory deficits in early-stage Parkinson’s disease (PD) using functional magnetic resonance imaging (fMRI)…
  • 2017 International Congress

    Patterns of Striatal DAT Binding Loss in a Progressing Parkinson Disease (PD) Cohort: Four year PPMI Follow-up

    J. Seibyl, K. Marek (New Haven, CT, USA)

    Objective: To evaluate within subject striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants studied over four years in the…
  • 2017 International Congress

    Normal “heart” in Parkinson’s disease: Is this a distinct clinical phenotype?

    J.E. Lee, J.-S. Kim, Y.-S. Oh, D.-W. Ryu, I.-U. Song, K.-S. Lee (Seoul, Republic of Korea)

    Objective: The aim of this study was to investigate whether non-motor manifestations of Parkinson’s disease (PD) differ between patients with normal and abnormal myocardial metaiodobenzylguanidine (MIBG)…
  • 2017 International Congress

    Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease.

    C. Friedrich, W. Zago, S. Gardai, G. Tonn, M. Reed (Cupertino, CA, USA)

    Objective: Objective: In order to improve the understanding of the alpha-synuclein system and its role in Parkinson’s disease, Elan and Rosa collaborated in the development…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley